Literature DB >> 11098411

Neuropharmacology of venlafaxine.

P H Roseboom1, N H Kalin.   

Abstract

Venlafaxine (Effexor) is an effective antidepressant and has also been approved for the treatment of generalized anxiety disorder. Venlafaxine was initially characterized as an inhibitor of both serotonin (5HT) and norepinephrine (NE) uptake and was therefore termed a "dual uptake inhibitor." This chapter reviews data from both in vitro and in vivo studies regarding its effects on 5HT and NE neurotransmission. In addition, the effects of venlafaxine on other systems that may play a role in its therapeutic efficacy effects are described. The data indicate that venlafaxine is a relatively weak inhibitor of NE transport in vitro. In vivo studies indicate that venlafaxine selectively inhibits 5HT uptake at low therapeutic doses and inhibits both 5HT and NE uptake at higher therapeutic doses. This chapter concludes with a discussion of the effects of venlafaxine on various aspects of physiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11098411     DOI: 10.1002/1520-6394(2000)12:1+<20::AID-DA3>3.0.CO;2-M

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  6 in total

1.  The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders.

Authors:  Domenic A Ciraulo; David H Barlow; Suzy Bird Gulliver; Todd Farchione; Sandra B Morissette; Barbara W Kamholz; Katherine Eisenmenger; Bonnie Brown; Eric Devine; Timothy A Brown; Clifford M Knapp
Journal:  Behav Res Ther       Date:  2013-08-30

2.  A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients.

Authors:  Wilfrid Noel Raby; Eric A Rubin; Fatima Garawi; Wendy Cheng; Ella Mason; Lisa Sanfilippo; Stephanie Lord; Adam Bisaga; Efrat Aharonovich; Frances Levin; David McDowell; Edward V Nunes
Journal:  Am J Addict       Date:  2013-06-26

3.  Time course of clinical response to venlafaxine: relevance of plasma level and chirality.

Authors:  Marianne Gex-Fabry; Androniki E Balant-Gorgia; Luc P Balant; Serge Rudaz; Jean-Luc Veuthey; Gilles Bertschy
Journal:  Eur J Clin Pharmacol       Date:  2003-12-24       Impact factor: 2.953

4.  Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.

Authors:  Katsumasa Muneoka; Yukihiko Shirayama; Morikuni Takigawa; Seiji Shioda
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

5.  Getting the balance right: Established and emerging therapies for major depressive disorders.

Authors:  Bojana Perović; Marija Jovanović; Branislava Miljković; Sandra Vezmar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

6.  Reduction of Methylphenidate Induced Anxiety, Depression and Cognition Impairment by Various doses of Venlafaxine in Rat.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Andia Ebrahimzadeh; Setare Farokhi Larijani; Zohreh Khajehamedi
Journal:  Int J Prev Med       Date:  2015-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.